Zymeworks removes CFO; Gilead extends Nurix deal
02 Apr 2024
Executive ChangeIPO
Plus, news about Onconova Therapeutics, Trawsfynydd Therapeutics, Nocion Therapeutics, Ginkgo Bioworks and Modulus Therapeutics:
Zymeworks ousts CFO:
The biotech
disclosed
Monday that it had removed CFO Christopher Astle on March 31, though did not provide a reason in an SEC filing. President and CEO Kenneth Galbraith is serving as interim CFO until the company finds a replacement. “Following careful consideration, and in the interest of our commitment to continuing our growth and success, the decision was made to initiate a search for a new CFO who possesses the specific experience, expertise and vision to drive our business strategies forward effectively,” a spokesperson wrote to
Endpoints
in an email. The company’s shares
$ZYME
fell about 4% on Tuesday.
— Lei Lei Wu
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.